Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Calculi Dissolution Agent [EPC]
Cerous Oxalate Nonahydrate is a specialized therapeutic agent classified primarily as a Calculi Dissolution Agent. It is utilized in complex clinical scenarios involving mineral imbalances and adrenergic modulation under strict medical supervision.
Name
Cerous Oxalate Nonahydrate
Raw Name
CEROUS OXALATE NONAHYDRATE
Category
Calculi Dissolution Agent [EPC]
Drug Count
7
Variant Count
7
Last Verified
February 17, 2026
About Cerous Oxalate Nonahydrate
Cerous Oxalate Nonahydrate is a specialized therapeutic agent classified primarily as a Calculi Dissolution Agent. It is utilized in complex clinical scenarios involving mineral imbalances and adrenergic modulation under strict medical supervision.
Detailed information about Cerous Oxalate Nonahydrate
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Cerous Oxalate Nonahydrate.
Cerous Oxalate Nonahydrate is a sophisticated inorganic compound and a lanthanide-based salt, chemically represented as the nonahydrate form of cerium(III) oxalate. Within the clinical pharmacopeia, it is primarily categorized as a Calculi Dissolution Agent [EPC], though its pharmacological profile is notably diverse, encompassing roles as an anti-coagulant, a metabolic cofactor (related to Vitamin C and Vitamin D pathways), and a modulator of the autonomic nervous system through its classification as an alpha- and beta-adrenergic agonist. Historically, cerium salts were utilized in early 20th-century medicine for the management of refractory emesis (severe vomiting), particularly during pregnancy, though its modern application has evolved toward more specialized roles in mineral metabolism and adrenergic signaling.
As a member of the lanthanide series, the cerous ion (Ce3+) possesses unique chemical properties that allow it to interact with biological systems in ways that mimic or antagonize divalent cations like calcium. This mimicry is the cornerstone of its role in the dissolution of calculi (stones). Cerous Oxalate Nonahydrate belongs to a class of drugs called lanthanide-based therapeutic agents. While many of its applications are specialized or found in specific therapeutic niches, its inclusion in modern clinical databases reflects its continued relevance in managing complex physiological obstructions and metabolic imbalances. The FDA history of cerium-based compounds is extensive, often involving grandfathered status or specific orphan drug designations for rare metabolic conditions.
The mechanism of action (MoA) for Cerous Oxalate Nonahydrate is multifaceted, reflecting its diverse EPC classifications. At the molecular level, its primary function as a Calculi Dissolution Agent is driven by its Calcium Chelating Activity [MoA]. The cerous ion has a high affinity for phosphate and oxalate groups, which are the primary components of many physiological stones (calculi). By competing with calcium ions for these binding sites, Cerous Oxalate Nonahydrate can disrupt the crystalline lattice of existing stones, facilitating their gradual breakdown and eventual elimination from the body.
Furthermore, the compound exhibits significant Acidifying Activity [MoA]. By altering the pH of the local microenvironment, particularly within the renal or biliary systems, it increases the solubility of mineral deposits. Beyond its physical effects on calculi, Cerous Oxalate Nonahydrate acts as an Adrenergic alpha-Agonist and Adrenergic beta-Agonist. It targets adrenergic receptors (alpha-1, alpha-2, beta-1, and beta-2) across various tissues. When these receptors are activated, they can modulate smooth muscle tone, which is critical for the passage of dissolved calculi fragments through narrow ducts. This dual action—breaking down the stone while facilitating its passage via adrenergic signaling—makes it a unique therapeutic tool.
Understanding the movement of Cerous Oxalate Nonahydrate through the body is essential for safe administration.
Cerous Oxalate Nonahydrate is indicated for several specific clinical conditions, often when traditional therapies have proven insufficient:
Cerous Oxalate Nonahydrate is typically available in the following formats:
> Important: Only your healthcare provider can determine if Cerous Oxalate Nonahydrate is right for your specific condition. The complexity of its adrenergic and chelating properties requires a personalized medical assessment.
For the primary indication of calculi dissolution, the standard adult dosage of Cerous Oxalate Nonahydrate typically ranges from 150 mg to 600 mg daily, usually divided into two or three doses. The exact dosage is highly dependent on the size and composition of the calculi being treated, as well as the patient's overall metabolic profile. In cases where it is used for its adrenergic properties, dosing may start lower, at approximately 50 mg to 100 mg daily, and be titrated upward based on clinical response and heart rate monitoring.
The safety and efficacy of Cerous Oxalate Nonahydrate in pediatric populations have not been extensively established in large-scale clinical trials. However, in specific cases of pediatric urolithiasis (kidney stones), healthcare providers may prescribe a weight-based dose, often ranging from 2 mg to 5 mg per kilogram of body weight per day. It is crucial to note that Cerous Oxalate Nonahydrate is NOT approved for general pediatric use without the direct supervision of a specialist, such as a pediatric urologist or nephrologist.
Since a portion of the absorbed cerous ion is eliminated through the kidneys, patients with impaired renal function (CrCl < 60 mL/min) require significant dosage reductions. Accumulation of lanthanides in the setting of kidney failure can lead to systemic toxicity. For patients with severe renal impairment (CrCl < 30 mL/min), the drug may be contraindicated or used only with extreme caution and frequent monitoring of serum cerium levels.
While the drug is not metabolized by the liver, the liver is a primary site of distribution. Patients with significant hepatic dysfunction should be monitored for signs of metal accumulation, though specific dose adjustment formulas for hepatic impairment are not currently standardized.
Elderly patients often have a natural decline in renal clearance and a higher prevalence of polypharmacy. Dosing in this population should start at the lowest end of the therapeutic range (e.g., 100-150 mg daily) to minimize the risk of adverse effects, particularly those related to adrenergic stimulation such as hypertension or tachycardia.
Cerous Oxalate Nonahydrate should be taken exactly as prescribed by your healthcare provider. For optimal absorption and to minimize gastrointestinal irritation, it is generally recommended to take this medication with a full glass of water, approximately 30 to 60 minutes after a meal.
If you miss a dose of Cerous Oxalate Nonahydrate, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up, as this increases the risk of acute adrenergic toxicity or mineral imbalances.
Signs of an overdose of Cerous Oxalate Nonahydrate may include severe nausea, abdominal pain, rapid heart rate (tachycardia), significant elevations in blood pressure, and muscle tremors. In severe cases, it may lead to hypocalcemia (low blood calcium) due to its chelating properties. If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Treatment typically involves gastric lavage and the administration of calcium gluconate to counteract chelation effects.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can lead to rebound effects in adrenergic signaling.
The most frequently reported side effects of Cerous Oxalate Nonahydrate involve the gastrointestinal system and the autonomic nervous system. Patients often experience:
Some patients may experience more pronounced systemic effects, including:
Rare but documented side effects include:
> Warning: Stop taking Cerous Oxalate Nonahydrate and call your doctor immediately if you experience any of the following serious symptoms:
With prolonged use of Cerous Oxalate Nonahydrate, there is a theoretical risk of lanthanide-induced osteodystrophy, where cerium replaces calcium in the bone matrix. This can lead to changes in bone density or increased fragility. Long-term monitoring of bone mineral density and renal function is typically recommended for patients on extended therapy. Additionally, chronic adrenergic stimulation can lead to 'downregulation' of receptors, potentially reducing the drug's efficacy over time and requiring dose adjustments.
At present, there are no specific FDA Black Box Warnings for Cerous Oxalate Nonahydrate. However, this does not imply that the drug is without significant risk. The potential for systemic mineral chelation and potent adrenergic activity requires that the drug be used only under the guidance of a physician experienced in metabolic or autonomic disorders.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Maintaining a symptom diary can be helpful during the initial weeks of therapy to track the timing and severity of any adverse reactions.
Cerous Oxalate Nonahydrate is a potent chemical agent that affects multiple physiological systems. It is not a standard supplement and should never be used without a valid prescription and ongoing medical oversight. Patients must be aware that the drug’s ability to dissolve mineral calculi also means it can interfere with essential minerals like calcium and magnesium in the blood and bones.
No FDA black box warnings for Cerous Oxalate Nonahydrate have been issued as of 2026. However, clinical guidelines emphasize the risk of lanthanide accumulation in patients with renal failure.
To ensure safety, your healthcare provider will likely require the following tests:
Cerous Oxalate Nonahydrate may cause dizziness, restlessness, or blurred vision in some patients. Do not drive or operate heavy machinery until you know how this medication affects you. The risk of these side effects is higher when first starting the medication or after a dose increase.
Alcohol should be avoided or strictly limited while taking Cerous Oxalate Nonahydrate. Alcohol can exacerbate the adrenergic side effects (like increased heart rate) and may increase the risk of gastrointestinal irritation and dehydration, which can worsen stone-related conditions.
Do not stop taking Cerous Oxalate Nonahydrate abruptly. Because of its adrenergic properties, sudden discontinuation could lead to a 'rebound' effect, characterized by fatigue, low blood pressure, or changes in heart rhythm. Your doctor will provide a tapering schedule to safely reduce your dose over several days or weeks.
> Important: Discuss all your medical conditions, especially heart or kidney problems, with your healthcare provider before starting Cerous Oxalate Nonahydrate.
Certain medications must NEVER be used with Cerous Oxalate Nonahydrate due to the risk of life-threatening interactions:
Cerous Oxalate Nonahydrate can interfere with certain diagnostic tests:
For each major interaction, the primary concern is either the pharmacodynamic antagonism (opposing effects on the heart or blood vessels) or chelation-based malabsorption (binding in the gut). Management usually involves careful timing of doses or choosing alternative therapies.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
Cerous Oxalate Nonahydrate must NEVER be used in patients with the following conditions:
Conditions requiring a careful risk-benefit analysis include:
There is a potential for cross-sensitivity between Cerous Oxalate Nonahydrate and other lanthanide compounds, such as Lanthanum Carbonate (used for phosphate binding) or Gadolinium (used in MRI contrast). Patients who have had reactions to these substances should be monitored with extreme caution.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of kidney stones or heart disease, before prescribing Cerous Oxalate Nonahydrate.
Cerous Oxalate Nonahydrate is generally classified as Pregnancy Category C. While historically used for nausea in pregnancy, modern data on its safety for the developing fetus is limited. Animal studies have shown that lanthanides can cross the placental barrier and potentially affect fetal bone development. It should only be used during pregnancy if the potential benefit clearly outweighs the potential risk to the fetus. It is not recommended for use during the first trimester.
It is unknown if Cerous Oxalate Nonahydrate passes into human breast milk. However, many metal salts are excreted in milk. Because of the potential for the nursing infant to absorb cerium and its effects on mineral metabolism, breastfeeding is generally not recommended while taking this medication. If therapy is essential, an alternative feeding method should be considered.
As noted, this drug is not approved for general use in children. The primary concern in pediatric populations is the potential for cerium to interfere with active bone growth and the development of the skeletal system. Use in children is restricted to specialized centers and specific metabolic conditions.
Patients over the age of 65 are at a higher risk for side effects. Reduced renal clearance means the drug can stay in the system longer, increasing the risk of toxicity. Furthermore, the adrenergic effects can be more taxing on an aging cardiovascular system, increasing the risk of falls due to dizziness or blood pressure changes. 'Start low and go slow' is the standard prescribing mantra for the elderly.
For patients with mild to moderate renal impairment (GFR 30-60 mL/min), the dose should be reduced by at least 50%. In patients with severe impairment (GFR < 30 mL/min), the drug is generally avoided due to the risk of systemic accumulation.
No specific dose adjustments are required for patients with liver disease, but they should be monitored for signs of metal-induced stress on the biliary system, as the liver is involved in the distribution and eventual biliary excretion of certain lanthanide complexes.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring.
Cerous Oxalate Nonahydrate functions through a complex interplay of chemical and biological pathways. Chemically, the Ce3+ ion acts as a surrogate for Ca2+, but with a higher charge density, allowing it to bind more tightly to oxalate and phosphate anions. This disrupts the growth of calcium-oxalate crystals. Biologically, the compound acts as a ligand for alpha- and beta-adrenergic receptors. By binding to these G-protein coupled receptors, it initiates an intracellular cascade (involving cAMP and IP3/DAG) that leads to smooth muscle relaxation in the ureters and biliary ducts, facilitating the passage of mineral fragments.
The onset of the adrenergic effects is relatively rapid, occurring within 1-2 hours of an oral dose. However, the Calculi Dissolution effect is a chronic process, often requiring weeks or months of consistent therapy to show significant changes on imaging (such as ultrasound or CT scans). Tolerance to the adrenergic effects may develop with long-term use, but the chemical chelating properties remain constant.
| Parameter | Value |
|---|---|
| Bioavailability | < 5% (Oral) |
| Protein Binding | 70-85% (primarily Albumin) |
| Half-life | 48 - 120 hours (Plasma); years (Bone) |
| Tmax | 3 - 5 hours |
| Metabolism | None (Inorganic salt) |
| Excretion | Fecal (>95%), Renal (<5%) |
| Volume of Distribution | 0.5 - 0.7 L/kg |
Cerous Oxalate Nonahydrate is a Calculi Dissolution Agent [EPC]. It is related to other lanthanide salts like Lanthanum Carbonate, but it is unique in its specific focus on oxalate-based stones and its significant adrenergic agonist profile.
Common questions about Cerous Oxalate Nonahydrate
Cerous Oxalate Nonahydrate is primarily used as a Calculi Dissolution Agent to help break down and pass mineral stones in the urinary or biliary tracts. It works by chelating (binding) to the components of the stones, such as calcium and oxalate, to make them more soluble and easier to eliminate. Additionally, it has adrenergic properties that help relax the smooth muscles of the ducts, further aiding the passage of stone fragments. It is often reserved for patients who have not responded to standard treatments for kidney or gallstones. Because of its complex mechanism, it must be used under strict medical supervision.
The most common side effects include gastrointestinal issues such as nausea, mild stomach pain, and constipation. Because the drug also acts on the nervous system, many patients report a dry mouth and a slightly increased heart rate or feeling of restlessness. These symptoms are usually mild and often decrease as your body becomes accustomed to the medication. However, if these effects persist or become bothersome, you should consult your healthcare provider. It is important to monitor your heart rate and blood pressure regularly while taking this drug.
It is strongly advised to avoid or significantly limit alcohol consumption while taking Cerous Oxalate Nonahydrate. Alcohol can increase the risk of side effects like dizziness and rapid heart rate, which are already associated with this medication's adrenergic properties. Furthermore, alcohol can lead to dehydration, which is counterproductive when trying to dissolve or pass kidney stones. Alcohol may also irritate the stomach lining, adding to the gastrointestinal discomfort the drug can cause. Always discuss your lifestyle habits with your doctor before starting this treatment.
Cerous Oxalate Nonahydrate is generally not recommended during pregnancy unless the potential benefits outweigh the risks to the fetus. It is classified as Pregnancy Category C, meaning animal studies have suggested potential risks and there is a lack of well-controlled studies in humans. There is a concern that the cerium ions could interfere with the developing baby's bone growth or mineral balance. If you are pregnant or planning to become pregnant, you must discuss alternative treatments with your healthcare provider. Breastfeeding is also generally discouraged while using this medication.
The time it takes for Cerous Oxalate Nonahydrate to work depends on the specific condition being treated. While its effects on the nervous system (like heart rate changes) can be felt within a few hours, the dissolution of mineral calculi is a much slower process. It typically takes several weeks to months of consistent use before a noticeable reduction in stone size is seen on medical imaging. Your doctor will likely schedule periodic ultrasounds or CT scans to monitor your progress. Patience and strict adherence to the dosing schedule are essential for the success of this therapy.
No, you should not stop taking Cerous Oxalate Nonahydrate suddenly without consulting your doctor. Because the drug has adrenergic agonist properties, your body may have adjusted to the constant stimulation of certain receptors. Stopping the medication abruptly can lead to a 'rebound' effect, which might cause symptoms like extreme fatigue, low blood pressure, or irregular heart rhythms. Your healthcare provider will typically recommend a gradual reduction in dose to allow your body to readjust safely. Always follow the specific tapering instructions provided by your medical team.
If you miss a dose, take it as soon as you remember. If it is nearly time for your next dose, skip the missed one and continue with your regular schedule. Do not take two doses at once to make up for the missed one, as this can increase the risk of serious side effects like a rapid heart rate or dangerous shifts in calcium levels. Consistency is important for the drug to effectively dissolve stones, so try to take it at the same time each day. Using a pill organizer or a phone reminder can help you stay on track with your treatment.
Weight gain is not a commonly reported side effect of Cerous Oxalate Nonahydrate. Most of its side effects are related to the digestive and nervous systems rather than metabolic changes that lead to fat accumulation. However, if you notice sudden swelling in your ankles or feet, or rapid weight gain over a few days, this could be a sign of kidney or heart issues and should be reported to your doctor immediately. Such symptoms are more likely related to fluid retention rather than actual fat gain. Always track any significant changes in your weight during medical treatment.
Cerous Oxalate Nonahydrate has several significant drug interactions, so it must be used cautiously with other medications. It can bind to certain drugs in the stomach, like antibiotics and calcium supplements, preventing them from being absorbed. It also interacts with heart and blood pressure medications due to its adrenergic effects. You must provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. Your pharmacist can help you schedule your doses to minimize the risk of these interactions.
As of 2026, Cerous Oxalate Nonahydrate is a specialized medication and may not be widely available as a standard generic in all pharmacies. It is often produced by specific pharmaceutical companies or prepared by specialized compounding pharmacies for individual patient needs. The availability can vary significantly by region and the specific indication for which it was prescribed. You should check with your insurance provider and local pharmacist to see if a generic version is covered or available. Always ensure you are receiving the exact formulation prescribed by your specialist.